%0 Journal Article
%A Cruzado, Josep M
%A Lauzurica, Ricardo
%A Pascual, Julio
%A Marcen, Roberto
%A Moreso, Francesc
%A Gutierrez-Dalmau, Alex
%A Andrés, Amado
%A Hernández, Domingo
%A Torres, Armando
%A Beneyto, Maria Isabel
%A Melilli, Edoardo
%A Manonelles, Anna
%A Arias, Manuel
%A Praga, Manuel
%T Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.
%D 2017
%U https://hdl.handle.net/10668/25186
%X Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial. Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium 110 pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft protocol biopsies. The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the CAL group (P = 0.07). However, there was a higher percentage of patients with iPTH  Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH 
%K hyperparathyroidism
%K kidney transplantation
%K paricalcitol
%K vitamin D
%~